Andrew Bishop
Director of Finance/CFO at ARCH BIOPARTNERS INC.
Net worth: 720 000 $ as of 29/04/2024
Network origin in Andrew Bishop first degree
Entity | Entity type | Industry | |
---|---|---|---|
The Schulich School of Business
17
| College/University | Other Consumer Services | 17 |
Public Company | Pharmaceuticals: Major | 9 | |
Bingley Capital, Inc.
Bingley Capital, Inc. Investment ManagersFinance Bingley Capital, Inc. is an Independent Private Equity/Venture Capital firm founded in 2009 by Stephan Bey. Bingley Capital, Inc. is headquartered in Toronto.
1
| Private Company | Investment Managers | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Andrew Bishop via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
FENNEC PHARMACEUTICALS INC. | Pharmaceuticals: Major | Chief Operating Officer | |
HELIX BIOPHARMA CORP. | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member | |
PTC THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
GENTIUM S.P.A. (ADR) | Pharmaceuticals: Major | Corporate Officer/Principal | |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Sales & Marketing | |
HONGHUA GROUP LIMITED | Oilfield Services/Equipment | Director/Board Member | |
Rotman School of Management | College/University | Undergraduate Degree Undergraduate Degree | |
SQZ BIOTECHNOLOGIES COMPANY | Biotechnology | Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Stone Asset Management Ltd.
Stone Asset Management Ltd. Investment ManagersFinance Stone Asset Management Ltd. (SAM) is a mutual fund manager and investment advisor headquartered in Toronto, Ontario. The firm is a wholly-owned subsidiary of Stone Investment Group Ltd., an independent, Canadian-owned financial services firm. SAM was founded by Richard Stone in 1999, and provides investment management services via distinctive investment mandates to institutional and private clients. The firm is advisor to the Stone family of mutual funds. | Investment Managers | Portfolio Manager-Equities | |
Intel Capital Corp.
Intel Capital Corp. Investment ManagersFinance Intel Capital Corp (Intel Capital) is a venture capital subsidiary of Intel Corp founded in 1991 by Les Vadasz, and Avram Miller. The firm is headquartered in Wilmington, Delaware. | Investment Managers | Corporate Officer/Principal | |
York University | College/University | Masters Business Admin Masters Business Admin | |
Queen's University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
SANTHERA PHARMACEUTICALS HOLDING AG | Pharmaceuticals: Major | Director/Board Member | |
University of British Columbia | College/University | Masters Business Admin Undergraduate Degree | |
University of Toronto | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
Carleton University | College/University | Graduate Degree | |
Wilfrid Laurier University | College/University | Undergraduate Degree Undergraduate Degree | |
Zhejiang University | College/University | Undergraduate Degree | |
University of Huddersfield | College/University | Undergraduate Degree | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
Institute of Chartered Financial Analysts, Inc. | Corporate Officer/Principal | ||
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
University Technologies International, Inc.
University Technologies International, Inc. Miscellaneous Commercial ServicesCommercial Services University Technologies International, Inc. offers commercialization services. It offers programs such as 321 sales academy, startup primer, and accelerator programs. The firm’s services include CEO roundtable, venture mentoring service of Alberta, intellectual property management, and funding support. The company is headquartered in Calgary, Canada. | Miscellaneous Commercial Services | Chief Executive Officer | |
Biogen Canada, Inc. | Corporate Officer/Principal | ||
BiognoSYS AG
BiognoSYS AG Packaged SoftwareTechnology Services BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland. | Packaged Software | Chairman | |
VERSAPAY CORPORATION | Regional Banks | Director of Finance/CFO | |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Pharmaceuticals: Major | Chairman | |
Athyrium Capital Management LP
Athyrium Capital Management LP Investment ManagersFinance Athyrium Capital Management LP (Athyrium) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Jeffrey A. Ferrell in 2008 as Athyrium Capital Management LLC and converted from a Delaware limited liability company to a Delaware limited partnership in 2015. Athyrium provides advisory services on a discretionary basis to its clients, which may include specific tailored vehicles and pooled investment vehicles intended for sophisticated investors and institutional investors. | Investment Managers | Consultant / Advisor | |
Ares Management (Cayman) Ltd. | Director/Board Member | ||
Yorkville Asset Management, Inc.
Yorkville Asset Management, Inc. Investment ManagersFinance Yorkville Asset Management, Inc. (Yorkville) is a Canadian independent investment firm headquartered in Toronto, Ontario. The firm was founded by Hussein Amad 2010. Yorkville aims to help high net worth individuals, foundations, institutions, and family offices achieve their financial goals through wealth management, estate and tax planning, portfolio management, and capital markets debt and equity advisory services. | Investment Managers | Portfolio Manager-Equities | |
LITU HOLDINGS LIMITED | Containers/Packaging | Director/Board Member | |
Nikko Asset Management Hong Kong Ltd.
Nikko Asset Management Hong Kong Ltd. Investment ManagersFinance Nikko Asset Management Hong Kong Ltd. (Nikko AM HK) is the wholly owned asset management subsidiary of Nikko Asset Management International Ltd., ultimately held by Sumitomo Mitsui Trust Holdings, Inc. (TYO: 8309) in Japan. Headquartered in Hong Kong, Nikko AM HK was founded in 2011 to manage units trusts registered and authorized in Hong Kong on behalf of individual and institutional investors. | Investment Managers | Chief Investment Officer | |
CIRCIO HOLDING ASA | Biotechnology | Chairman | |
ADVANZ PHARMA CORP. LIMITED | Pharmaceuticals: Major | Director/Board Member | |
Gentium GmbH | Chief Operating Officer | ||
OZNER WATER INTERNATIONAL HOLDING LIMITED | Industrial Machinery | Director/Board Member | |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Other | Chairman | |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Chairman | |
Essential Pharmaceuticals LLC
Essential Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Intas Pharmaceuticals Ltd., Essential Pharmaceuticals LLC is a company that manufactures and markets pharmaceutical products. The company is based in Durham, NC. The company was founded in 2006. Emma Jane Johnson has been the CEO of the company since 2023. Essential Pharmaceuticals was acquired by Accord Healthcare, Inc. on July 26, 2017. | Pharmaceuticals: Major | Chairman | |
Essential Pharmaceuticals Ltd.
Essential Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Essential Pharmaceuticals Ltd. manufactures pharmaceutical products. The company was founded on November 24, 2010 and is headquartered in Egham, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Gyrus Capital SA | Investment Managers | Private Equity Investor | |
AMRYT PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
PTC Therapeutics Ltd.
PTC Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Founded in 2012, PTC Therapeutics Ltd. is a British pharmaceutical company that develops pharmaceutical products. Part of PTC Therapeutics, Inc., the company is based in London, UK. | Pharmaceuticals: Major | Director/Board Member | |
Hempsana Holdings Ltd.
Hempsana Holdings Ltd. Pharmaceuticals: OtherHealth Technology Hempsana Holdings Ltd. manufactures cannabis derivatives. It also engages in producing cannabis extracts for use in finished products, including vapeables, topical creams and infused consumables. The company was founded by Randy Ko and Sohil Mana on October 15, 2018 and is headquartered in Toronto, Canada. | Pharmaceuticals: Other | Director of Finance/CFO | |
Emera Capital Corp. | President | ||
F2g Inc. | Director/Board Member |
Statistics
International
Canada | 17 |
United States | 10 |
United Kingdom | 8 |
Switzerland | 6 |
Hong Kong | 4 |
Sectoral
Health Technology | 21 |
Consumer Services | 11 |
Finance | 9 |
Non-Energy Minerals | 2 |
Industrial Services | 2 |
Operational
Director/Board Member | 96 |
Corporate Officer/Principal | 53 |
Independent Dir/Board Member | 26 |
Masters Business Admin | 21 |
Undergraduate Degree | 20 |
Most connected contacts
Insiders | |
---|---|
Patrick Volkert Vink | 30 |
Kevin Talbot | 28 |
Paul Cataford | 23 |
David Fuller | 22 |
Adrian Haigh | 15 |
Geoffrey Rotstein | 14 |
Xing He | 12 |
Kong Chin Kok | 10 |
Claude Allary | 10 |
Chung Pong Li | 10 |
Michael Andrade | 9 |
Rachel H. Volynsky | 7 |
Phil Taller | 7 |
Kirk Exner | 7 |
Richard Muruve | 6 |
- Stock Market
- Insiders
- Andrew Bishop
- Company connections